TrialInvestigational new drugs2014

A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.

Arun A Azad et al.PubMed ↗Publisher ↗

No numbers read from the abstract.